Micrus' ACT MicroCoil Aimed At Target Therapeutics' Embolization Market
This article was originally published in The Gray Sheet
Micrus Corp. is hoping that data from upcoming clinical trials of the ACT MicroCoil delivery system will demonstrate superiority to Target Therapeutics' Guglielmi Detachable Coil.
You may also be interested in...
The Pink Sheet explains the procedures underpinning the UK’s emergency use authorization of the Pfizer/BioNTech COVID-19 vaccine.
The US Food and Drug Administration posted two device-related closeout letters in November.
Jazz and PharmaMar need to see what further data will be needed to convert their FDA authorization into a full approval following disappointing results in the ATLANTIS Phase III trial.